Fifth Third Bancorp Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Fifth Third Bancorp raised its stake in Regeneron by 27.9%, buying 3,362 shares to hold 15,425 shares valued at about $11.91 million.
• Regeneron reported a stronger-than-expected Q1 (revenue +19%, EPS $9.47 vs. $8.91) and announced a $3 billion buyback, but shares fell amid a 10% drop in net income and mixed analyst reactions; the consensus is a "Moderate Buy" with an average price target near $826.59.
• The company declared a quarterly dividend of $0.94 (annualized $3.76, ~0.5% yield), while insiders have sold about 3,774 shares valued at roughly $2.94 million over the last 90 days.

Fifth Third Bancorp boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 27.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,425 shares of the biopharmaceutical company's stock after buying an additional 3,362 shares during the period. Fifth Third Bancorp's holdings in Regeneron Pharmaceuticals were worth $11,906,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Danske Bank A S boosted its position in Regeneron Pharmaceuticals by 78.8% in the fourth quarter. Danske Bank A S now owns 99,302 shares of the biopharmaceutical company's stock valued at $76,648,000 after buying an additional 43,775 shares during the last quarter. GenTrust LLC purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $439,000. Citizens Business Bank raised its position in Regeneron Pharmaceuticals by 1.0% during the fourth quarter. Citizens Business Bank now owns 6,182 shares of the biopharmaceutical company's stock valued at $4,772,000 after acquiring an additional 63 shares in the last quarter. Oppenheimer & Co. Inc. raised its position in Regeneron Pharmaceuticals by 4.5% during the fourth quarter. Oppenheimer & Co. Inc. now owns 24,792 shares of the biopharmaceutical company's stock valued at $19,136,000 after acquiring an additional 1,078 shares in the last quarter. Finally, Sigma Planning Corp raised its position in Regeneron Pharmaceuticals by 50.6% during the fourth quarter. Sigma Planning Corp now owns 774 shares of the biopharmaceutical company's stock valued at $597,000 after acquiring an additional 260 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and announced a $3 billion share buyback — fundamentals and the buyback are clear upside catalysts for shareholder value. Regeneron reports strong Q1 CY2026
• Positive Sentiment: Guggenheim raised its price target to $995 and retained a Buy — that implies sizable upside and supports sentiment among growth/value investors. Guggenheim raises REGN target to $995
• Neutral Sentiment: Zacks highlights REGN as a long-term value pick — supportive narrative for buy-and-hold investors but not an immediate price catalyst. Why Regeneron is a Top Value Stock
• Neutral Sentiment: Several banks trimmed price targets modestly (Barclays, Truist, Wells Fargo) but largely kept positive/market-weight ratings — suggests analysts revised models after Q1 details but remain constructive overall. Analyst PT changes after Q1
• Negative Sentiment: Royal Bank of Canada cut its target to $762 and moved to a "sector perform" stance — a more cautious view that likely weighed on intraday selling pressure. RBC lowers REGN target to $762
• Negative Sentiment: Coverage and model cuts followed the Q1 release despite the beat; investors focused on items such as a 10% drop in net income year-over-year (even as revenue rose), which may have trimmed near-term expectations. Regeneron Q1 2026 net income falls 10%
• Negative Sentiment: Market reaction: shares fell despite the beat — coverage (Seeking Alpha) points to investor disappointment or guidance/forward assumptions as the reason for the drop. That momentum explains today's weaker price action. Regeneron drops despite Q1 beat

Analysts Set New Price Targets

REGN has been the subject of several recent research reports. Oppenheimer reiterated an "outperform" rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. JPMorgan Chase & Co. lifted their price target on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an "overweight" rating in a research report on Monday, February 2nd. Bank of America upgraded Regeneron Pharmaceuticals from an "underperform" rating to a "buy" rating and lifted their price target for the company from $627.00 to $860.00 in a research report on Wednesday, January 7th. Guggenheim lifted their price target on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a "buy" rating in a research report on Friday. Finally, Evercore boosted their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an "outperform" rating in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $826.59.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $701.42 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 3.39. The business's 50 day moving average price is $756.81 and its 200-day moving average price is $736.41. The firm has a market capitalization of $74.15 billion, a PE ratio of 17.09, a P/E/G ratio of 1.61 and a beta of 0.30. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business's revenue was up 19.0% on a year-over-year basis. During the same period in the previous year, the company posted $8.22 earnings per share. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.05 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be paid a $0.94 dividend. The ex-dividend date of this dividend is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is currently 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the sale, the director directly owned 17,803 shares of the company's stock, valued at $13,860,169.59. The trade was a 0.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Jason Pitofsky sold 2,036 shares of the business's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. This trade represents a 32.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,774 shares of company stock valued at $2,942,738 over the last ninety days. Insiders own 7.02% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.